Alessandro Verrecchia

Curriculum Vitae

PERSONAL DETAILS

Date of birth:
January 22nd 1963
Address:
Viale Omero 22
20139 Milano (Italy)
M: +39 340 96 25 530
E: averrecc@gmail.com

SKILLS AND TECHNIQUES

- **Gene Cloning**
- **Retro- and lentiviral vectors infections**
- **Genome wide shRNAs screening**
- **CRISPR/Cas9 technology (gene knockout, gene tagging, CRISPRa, CRISPRi)**
- **shRNAs libraries for Illumina sequencing**
- **RNA expression analysis**
- **Quantitative PCR**
- **ChIP**
- **Cell culture techniques**
- **Basic FACS analysis**
- **Cell sorting**
- **Western Blot analysis**
- **R statistical analysis**
- **Lab management**

SUMMARY

I obtained a Master's Degree in Pharmacy in 1988 and a Postgraduate Qualification in Experimental Endocrinology in 1991 from University of Milano (Italy)
I started my career as a research technician at DiBit, San Raffaele Hospital, in Claudio Bordignon's laboratory of Gene Therapy, moving later to the Telethon Institute of Gene Therapy (TIGET) where I continued working on gene transfer in human and mouse cells using retro and lentiviral vectors.
In 2014 I joined Bruno Amati's laboratory at the European Institute of Oncology (IEO), where I strengthened my skills in molecular biology techniques. In particular I am the lab reference for designing and implementing CRISPR-Cas9-based technology

CURRENT POSITION

From 2004 Research Technician / Research Assistant,
Laboratory of Dr. Bruno Amati,
European Institute of Oncology, Milan, Italy

ACADEMIC QUALIFICATIONS

1991 Post-graduated in Experimental Endocrinology,
Facolta' di Farmacia, Universita' Statale di Milano, Italy
1988 Graduated in Pharmacy,
Facolta' di Farmacia, Universita' Statale di Milano, Italy

PROFESSIONAL AND RESEARCH EXPERIENCES

2002-2003 Molmed spa (Biotech company)
San Raffaele Hospital, Milan, Italy
Research Technician

1999-2002 Genera spa (Biotech company)
San Raffaele Hospital, Milan, Italy
Research Technician

1996-1999 T.I.G.E.T (Telethon Institute for Gene Therapy)
San Raffaele Hospital, Milan, Italy
Research Technician

1992-1996 Experimental Hematology and Gene Therapy Lab.
San Raffaele Hospital, Milan, Italy
Fellow

1989-1992 Experimental Toxicology Lab.
Istituto Mario Negri, Milan, Italy
Fellow

SELECTED COURSES AND MEETINGS

3-4th May 2016	Revolutionary Science Day "CRISPR connects your next discovery" Geneva, Switzerland
26th May 2015	Statistics and R for the Life Sciences certification for the course of study offered by HarvardX, an online learning initiative of Harvard University through edX
14-17th November 2012	Targeted Genome Editing Using Zinc Finger Nucleases EMBL, Advanced Training Center Heidelberg, Germany

LIST OF PUBBLICATIONS

Tesi A, de Pretis S, Furlan M, Filipuzzi M, Morelli MJ, Andronache A, Doni M, Verrecchia A, Pelizzola M, Amati B, Sabò A.
An early Myc-dependent transcriptional program orchestrates cell growth during B-cell activation.
EMBO Rep. 2019 Sep;20(9):e47987

Croci O, De Fazio S, Biagioni F, Donato E, Caganova M, Curti L, Doni M, Sberna S, Aldeghi D, Biancotto C, Verrecchia A, Olivero D, Amati B, Campaner S.
Transcriptional integration of mitogenic and mechanical signals by Myc and YAP.
Genes Dev. 2017 Oct 15;31(20):2017-2022

de Pretis S, Kress TR, Morelli MJ, Sabò A, Locarno C, Verrecchia A, Doni M, Campaner S, Amati B, Pelizzola M.
Integrative analysis of RNA polymerase II and transcriptional dynamics upon MYC activation.
Genome Res. 2017 Oct;27(10):1658-1664

Tonelli C, Morelli MJ, Sabò A, Verrecchia A, Rotta L, Capra T, Bianchi S, Campaner S, Amati B.
Genome-wide analysis of p53-regulated transcription in Myc-driven lymphomas
Oncogene. 2017 May 25;36(21):2921-2929.

Kress TR, Pellanda P, Pellegrinet L, Bianchi V, Nicoli P, Doni M, Recordati C, Bianchi S, Rotta L, Capra T, Ravà M, Verrecchia A, Radaelli E, Littlewood TD, Evan GI, Amati B.
Identification of MYC-Dependent Transcriptional Programs in Oncogene-Addicted Liver Tumors
Cancer Res. 2016 Jun 15;76(12):3463-72

D'Artista L, Bisso A, Piontini A, Doni M, Verrecchia A, Kress TR, Morelli MJ, Del Sal G, Amati B, Campaner S.
Pin1 is required for sustained B cell proliferation upon oncogenic activation of Myc
Oncotarget. 2016 Apr 19;7(16):21786-98

Sabò A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A, Morelli MJ, Bora P, Doni M, Verrecchia A, Tonelli C, Fagà G, Bianchi V, Ronchi A, Low D, Müller H, Guccione E, Campaner S, Amati B.
Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis
Nature. 2014 Jul 24;511(7510):488-92

Sanchez-Arévalo Lobo VJ, Doni M, Verrecchia A, Sanulli S, Fagà G, Piontini A, Bianchi M, Conacci-Sorrell M, Mazzarol G, Peg V, Losa JH, Ronchi P, Ponzoni M, Eisenman RN, Doglioni C, Amati B.
Dual regulation of Myc by Abl
Oncogene. 2013 Nov 7;32(45):5261-71

LIST OF PUBBLICATIONS

Perna D, Fagà G, Verrecchia A, Gorski MM, Barozzi I, Narang V, Khng J, Lim KC, Sung WK, Sanges R, Stupka E, Oskarsson T, Trumpp A, Wei CL, Müller H, Amati B.
Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts
Oncogene. 2012 Mar 29;31(13):1695-709

Campaner S, Doni M, Verrecchia A, Fagà G, Bianchi L, Amati B.
Myc, Cdk2 and cellular senescence: Old players, new game
*Cell Cycle***.** 2010 Sep 15;9(18):3655-61

Pistoni M, Verrecchia A, Doni M, Guccione E, Amati B.
Chromatin association and regulation of rDNA transcription by the Ras-family protein RasL11a
EMBO J. 2010 Apr 7;29(7):1215-24

Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D, Schleker T, Perna D, Tronnersjö S, Murga M, Fernandez-Capetillo O, Barbacid M, Larsson LG and Bruno A
Cdk2 suppresses cellular senescence induced by the c-myc oncogene
Nat Cell Biol. 2010 Jan;12(1):54-9

Smith AP, Verrecchia A., Faga` G., Doni M., Perna D., Martinato F., Guccione E. and Amati B.
A positive role for Myc in TGFb-induced Snail transcription and epithelial-to-mesenchymal transition
Oncogene. 2009 Jan 22;28(3):422-30.

Di Micco R, Cicalese A., Fumagalli M., Dobreva M., Verrecchia A., Pelicci P.G. and d'Adda di Fagagna F.
DNA damage response activation in mouse embryonic fibroblasts undergoing replicative senescence and following spontaneous immortalization
Cell Cycle. 2008 Nov 15;7(22):3601-6

Gorrini C., Squatrito M., Luise C., Syed N., Perna D., Wark L, Martinato F., Sardella D., Verrecchia A., Bennett S., Confalonieri S., Cesaroni M., Marchesi F., Gasco M, Scanziani E., Capra M., Mai S., Nuciforo P., Crook T., Lough J. and Amati B.
Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response
Nature. 448(7157): 1063-67 (2007)

Lupetti R., Pisarra P., Verrecchia A., Farina C., Nicolini G., Anichini A., Bordignon C., SensiM.L., Parmiani G., and Traversari C.
Translation of a retained intron in tyrosinase-related protein (TRP)2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage
J Exp Med. 188, 6, 1005-1016 (1998).

Traversari C., Meazza R., Coppolecchia M., Basso S., Verrecchia A., van der Bruggen P., Ardizzoni A., Gaggero A., and Ferrini S.
IFN-g gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA- deficient cell lung cancer
Gene Therapy. 4, 1029-1035 (1997).

Russo V, Traversari C, Verrecchia A, Mottolese M, Natali PG, Bordignon C.
Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy
Int J Cancer. 1995 Jun 22;64(3):216-21.

Verrecchia A, Guaitani A.
Insulin-mimetic effects of vanadate in preventing the increase of P450IIIA and P450IA subfamily proteins in streptozotocin-diabetic rats
Acta Diabetol. 1993; 30(3):128-31.